JB
Juliana Bacigalupi
Also known as: Juliana Craig
Research areas: Medicine · Oncology · CAR-T cell therapy research · T-cell and B-cell Immunology · Lymphoma Diagnosis and Treatment
0000-0002-5644-2292
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (28)
- Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial Save
- Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC Save
- Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy Save
- Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era Save
- Abstract 3603: Reverse fate mapping of CD19-targeted CAR T cells in patients with large B-cell lymphoma Save
- Chimeric Antigen Receptor t-Cell (CAR-T) Therapy Recipients and Worsening Financial Impact over Time: A Mixed Methods Longitudinal Study Save
- Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy Save
- Proinflammatory Cytokines are Associated with CAR-22 Macrophage Activation Syndrome Save
- Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma Save
- Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy Save
- CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy Save
- Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy Save
- Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study Save
- Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial Save
- CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial Save
- Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma Save
- CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma Save
- Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity Save
- CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute … Save
- Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma Save